Delcath Systems, Inc. DCTH 深 滬
等待開盤 01-29 09:30:00 美东时间
9.92
-0.290
-2.84%
華盛通- 最 高10.24
- 今 開10.22
- 成交量 51.47万股
- 最 低 9.91
- 昨 收 10.21
- 總市值 3.50亿
- 52周最高 18.23
- 市盈率 靜 --
- 換手率 1.46%
- 52周最低 8.12
- 委 比 1.37%
- 總股本 3531.37万
- 歷史最高 9368800000.00
- 量 比 1.26
- 振 幅 3.23%
- 歷史最低 2.25
- 每 手 1
- 風險率 2.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
HC Wainwright & Co. Reiterates Buy on Delcath Systems, Maintains $30 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $30 price target.
01-10 01:30
Delcath Systems Publishes Phase 3 FOCUS Subgroup Analyses Showing Consistent Efficacy And Safety Of HEPZATO KIT In Unresectable Metastatic Uveal Melanoma In The Journal Of Cancer Research And Clinical Oncology
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from
2025-12-31 21:03
Delcath Systems 10-Year Data From Retrospective Study On Patients With Liver-Dominant Metastatic Uveal Melanoma Shows Safety, Efficacy Of CHEMOSAT
Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective
2025-12-04 05:06
Delcath Systems Announces $25M Buyback Plan
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath") an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a
2025-11-21 05:02
Delcath Systems Announces Retrospective Study From The University Of Tubingen, Analyzing Long-Term Survivors With Liver Metastases From Uveal Melanoma
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a
2025-11-13 21:39
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
Delcath Systems shares are trading lower after the company reported mixed Q3 financial results.
Delcath Systems shares are trading lower after the company reported mixed Q3 fi...
2025-11-05 01:24
BTIG Reiterates Buy on Delcath Systems, Maintains $23 Price Target
BTIG analyst Marie Thibault reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $23 price target.
2025-11-05 01:10
